-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

622.O2.6 622. Lymphomas: Translational–Non-Genetic: Translational Research in Lymphoma: Prognostic Biomarkers and Novel Therapeutic Vulnerabilities

Symposia: Lymphomas: Translational–Non-Genetic Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Hodgkin lymphoma, Biological therapies, Viral, adult, Translational Research, Lymphomas, non-Hodgkin lymphoma, B Cell lymphoma, Combination therapy, genomics, bioinformatics, blood banking, Checkpoint Inhibitor, drug development, pediatric, Diseases, indolent lymphoma, immune mechanism, cell expansion, aggressive lymphoma, Therapies, Infectious Diseases, immunology, Immunotherapy, Lymphoid Malignancies, metabolism, computational biology, Biological Processes, microbiome, emerging technologies, Monoclonal Antibody Therapy, molecular biology, Technology and Procedures, Study Population, profiling, Human, pathogenesis, imaging, omics technologies
Sunday, December 11, 2022: 12:00 PM-1:30 PM
Great Hall AD (Ernest N. Morial Convention Center)
Moderators:
James Godfrey, MD, City of Hope and Anamarija M. Perry, MD, University of Michigan
Disclosures:
Godfrey: Secura Bio: Research Funding; Merck: Research Funding.
12:00 PM

Stefano Luminari, MD1, Luca Guerra, MD2*, Carla Minoia, PhD3*, Stephane Chauvie, PhD4*, Antonella Anastasia5*, Federica Cavallo, MD6*, Paolo Corradini, MD7, Sara Rattotti8*, Rexhep Durmo9*, Chiara Ghiggi, MD10*, Jacopo Olivieri, MD11*, Simone Ferrero, MD12, Gloria Margiotta Casaluci, MD13*, Luca Nassi, MD14*, Caterina Stelitano15*, Francesca Ricci, MD16*, Vittorio Ruggero Zilioli, MD17*, Antonio Pinto, MD18,19*, Manuela Zanni, MD, PhD20*, Bolis Silvia, MD21*, Caterina Patti, MD22*, Michele Merli, MD23,24*, Annalisa Chiarenza25*, Gerardo Musuraca, MD, PhD26*, Patrizia Tosi, MD27*, Massimo Federico, MD28 and Annibale Versari, MD29*

1Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Italy
2Nuclear Medicine, University of Milan Bicocca, Monza, Monza, Italy
3Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy
4Medical Phyhsics Department, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy
5Hematology, ASST Spedali Civili, Brescia, Italy
6Department of Molecular Biotechnologies and Health Sciences, Division of Hematology, University of Torino, Turin, Italy
7Università degli Studi di Milano and Fondazione Istituti di Ricovero e Cura a Carattere Scientifico (IRCSS) Istituto Nazionale dei Tumori, Milan, Italy
8Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
9Nuclear Medicine Unit, Azienda USL-IRCCS di Reggio Emilia, Italy, Reggio Emilia, Italy
10Hematology unit IRCCS Policlinico San Martino, Genova, Italy
11SOC Clinica Ematologica, Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), Udine, Italy
12Department of Molecular Biotechnologies and Health Sciences, Division of Hematology, University of Torino, Torino, Italy
13Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy
14Department of Hematology, AOU Careggi, Florence, Italy
15Division of Hematology, Azienda Ospedaliera "Bianchi Melacrino Morelli", Reggio Calabria, Italy
16Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
17Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, IT-MI, Italy
18Istituto Nazionale Tumori IRCCS, "Fondazione G. Pascale", Napoli, Italy
19Hematology-Oncology & Stem Cell Transplantation Unit, National Cancer Institute, Fondazione Pascale, IRCCS, Naples, Italy
20Hematology, AO SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
21Hematology, S. Gerardo University Hospital, ASST Monza, Monza, Italy
22Division of Hematology, A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy
23Hematology, Ospedale di Circolo e Fondazione Macchi, Varese, Italy
24Division of Hematology, University Hospital Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, University of Insubria, Varese, Italy
25Divisione di Ematologia, Ospedale Ferrarotto, A.O.U. Policlinico-OVE, Università di Catania, Catania, Italy
26Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
27Hematology Unit, Infermi Hospital Rimini, Rimini, Italy
28CHIMOMO department, Università degli Studi di Modena e Reggio Emilia, Modena, Italy
29Nuclear Medicine Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy

12:15 PM

Maare Arffman, MSc1,2*, Leo Meriranta, MD1,2*, Harald Holte, MD, PhD3,4, Judit Jørgensen, MD, PhD5*, Peter De Nully Brown, MD6, Sirkku Jyrkkio, MD, PhD7*, Mats Jerkeman, MD, PhD8, Øystein Fluge, MD, PhD9*, Magnus Björkholm, MD, PhD10, Matias Autio1,2*, Suvi-Katri Leivonen, PhD1,2 and Sirpa Leppa, MD, PhD1,2

1Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
2Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland
3KG. Jebsen Centre for B cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway
4Department of Oncology, Oslo University Hospital, Oslo, Norway
5Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
6Department of Hematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
7Turku University Hospital, Turku, Finland
8Skane University Hospital and Lund University, Lund, Skaane Laen, Sweden
9Haukeland University Hospital, Bergen, Norway
10Department of Medicine, Karolinska University Hospital, Stockholm, Sweden

12:30 PM

Andrea Garofalo1*, Stefan K. Alig, MD2, Joseph Schroers-Martin, MD3, Ragini Malika Shyam, MD4*, Mari Olsen2*, David M. Kurtz, MD, PhD5,6, Cédric Rossi, MD, PhD7*, Andre Schultz, PhD8*, Karan R. Kathuria2*, Chih Long Liu, PhD9*, Valeria Spina10*, Jamie E. Flerlage, MD, MS11, Sharon M. Castellino, MD, MSc12, Ranjana H. Advani, MD13, Davide Rossi, MD, PhD14, Ryan C. Lynch, MD15, Olivier Casasnovas, MD7*, Lianna J. Marks, MD16, Michael P. Link, MD17, Marc Andre, MD18*, Peter Vandenberghe, MD, PhD19, Christian Steidl20*, Maximilian Diehn, MD, PhD21* and Ash A. Alizadeh, MD, PhD22

1Divisions of Oncology and Hematology, Department of Medicine, Stanford University, Stanford, CA
2Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA
3Stanford University, Stanford, CA
4Stanford University Cancer Center, Los Altos, CA
5Department of Medicine, Divisions of Hematology & Oncology, Stanford University, Stanford, CA
6Stanford University, Palo Alto, CA
7Hematology Department, University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, France
8Foresight Diagnostics, Aurora, CO
9Divisions of Oncology and Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
10Institute of Oncology Research, Bellinzona, Switzerland
11Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
12Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta, GA
13Department of Medicine, Division of Oncology, Stanford University, Stanford, CA
14Amedeo Avorgadro Univ. of Eastern Piedmont, Bellinzona, Italy
15Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA
16Department of Pediatrics, Stanford University, Stanford, CA
17Department of Pediatrics, Stanford University, Palo Alto, CA
18Department of Haematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium
19University of Leuven, Leuven, Belgium
20Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada
21Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA
22Department of Medicine, Divisions of Hematology & Oncology, Stanford University Medical Center, Stanford, CA

12:45 PM

Nitin Agarwal, PhD1*, Akanksha Aradhya1*, Mario L. Marques-Piubelli, MD2*, Luisa M Solis Soto, MD2*, Daniel Bilbao, PhD3, Ralf Landgraf, PhD4*, Vida Ravanmehr5*, Jared Henderson, PhD5*, Michael R. Green, PhD5, Eric Davis, MD5* and Francisco Vega, MD, PhD1

1Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
3University of Miami, Miami, FL
4Department of Biochemistry and Molecular Biology, University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL
5Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

1:00 PM

Nicolas Di Siervi, PhD1, Maria Victoria Revuelta, PhD1*, Maria Teresa Cacciapuoti2*, Nahuel Zamponi, PhD2, Rossella Marullo, MD, PhD3, Ari Melnick, MD4, Giorgio Inghirami, MD5* and Leandro Cerchietti, MD6

1Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY
2Weill Cornell Medicine, New York, NY
3Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY
4Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY
5Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY
6Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medical College, New York, NY

1:15 PM

Ferran Araujo-Ayala1,2*, Cèlia Dobaño-López, MSc1,2*, Juan G Valero, PhD1,2*, Ferran Nadeu, PhD1,2*, Fabien Gava, PhD3*, Carla Faria, PhD3*, Marine Norlund, PhD4*, Renaud Morin, PhD4*, Pascale Bernes-Lasserre4*, Neus Serrat, MD, PhD1*, Heribert Playa-Albinyana, MSc, BSc1,2,5*, Rubén Giménez, MSc1,2*, Elías Campo, PhD MD1,2,5,6, Jean Michel Lagarde, PhD4*, Armando López-Guillermo, MD, PhD1,2,5,7*, Eva Giné, MD, PhD1,2,7, Dolors Colomer, PhD1,2,5,6*, Christine Bezombes, PhD3* and Patricia Pérez-Galán, PhD1,2*

1Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
3Centre de Recherches en Cancérologie de Toulouse, INSERM, Toulouse, France
4IMACTIV-3D, Toulouse, France
5University of Barcelona, Barcelona, Spain
6Hematopathology Section, Pathology Department, Hospital Clinic, Barcelona, Spain
7Hematology Department, Hospital Clínic, Barcelona, Spain

*signifies non-member of ASH